EA Mittendorf

605 total citations
44 papers, 427 citations indexed

About

EA Mittendorf is a scholar working on Oncology, Cancer Research and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, EA Mittendorf has authored 44 papers receiving a total of 427 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 26 papers in Cancer Research and 13 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in EA Mittendorf's work include Breast Cancer Treatment Studies (22 papers), Immunotherapy and Immune Responses (13 papers) and Cancer Immunotherapy and Biomarkers (13 papers). EA Mittendorf is often cited by papers focused on Breast Cancer Treatment Studies (22 papers), Immunotherapy and Immune Responses (13 papers) and Cancer Immunotherapy and Biomarkers (13 papers). EA Mittendorf collaborates with scholars based in United States, Switzerland and Japan. EA Mittendorf's co-authors include Sathibalan Ponniah, Jarrod P. Holmes, George E. Peoples, Erika J Schneble, Guy T. Clifton, David Van Echo, Thomas A. Buchholz, Paolo Tarantino, Giuseppe Curigliano and Khandan Keyomarsi and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

EA Mittendorf

42 papers receiving 416 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
EA Mittendorf United States 8 292 203 121 101 80 44 427
Rachel Marty Pyke United States 8 308 1.1× 266 1.3× 122 1.0× 172 1.7× 40 0.5× 17 506
Winifred Lo United States 8 289 1.0× 181 0.9× 64 0.5× 138 1.4× 49 0.6× 15 455
Annegé Vledder Netherlands 4 404 1.4× 307 1.5× 103 0.9× 139 1.4× 32 0.4× 9 626
Jennifer McDevitt United States 9 207 0.7× 105 0.5× 42 0.3× 126 1.2× 64 0.8× 22 338
Ningning Dong China 11 178 0.6× 70 0.3× 142 1.2× 194 1.9× 99 1.2× 20 479
Puay Hoon Tan Singapore 10 213 0.7× 144 0.7× 98 0.8× 135 1.3× 19 0.2× 17 387
B. Szynglarewicz Poland 11 225 0.8× 101 0.5× 132 1.1× 67 0.7× 31 0.4× 52 407
Makda Zewde United States 11 222 0.8× 164 0.8× 64 0.5× 164 1.6× 29 0.4× 16 443
Anna Spille Germany 6 504 1.7× 436 2.1× 52 0.4× 64 0.6× 27 0.3× 6 660
Yun Hua Lee Singapore 5 291 1.0× 212 1.0× 65 0.5× 97 1.0× 19 0.2× 5 571

Countries citing papers authored by EA Mittendorf

Since Specialization
Citations

This map shows the geographic impact of EA Mittendorf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by EA Mittendorf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites EA Mittendorf more than expected).

Fields of papers citing papers by EA Mittendorf

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by EA Mittendorf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by EA Mittendorf. The network helps show where EA Mittendorf may publish in the future.

Co-authorship network of co-authors of EA Mittendorf

This figure shows the co-authorship network connecting the top 25 collaborators of EA Mittendorf. A scholar is included among the top collaborators of EA Mittendorf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with EA Mittendorf. EA Mittendorf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Corti, Chiara, Anthony R. Martin, Jorge Gómez Tejeda Zañudo, et al.. (2025). Clinicopathological features and genomics of ER-positive/HER2-negative breast cancer relapsing on adjuvant abemaciclib. ESMO Open. 10(6). 105126–105126. 1 indexed citations
2.
Harbeck, Nadia, Chaojun Duan, Kelly DuPree, et al.. (2023). 2232O Atezolizumab (atezo) and tumour microenvironment in early triple-negative breast cancer (eTNBC): Exploratory biomarker analysis from IMpassion031. Annals of Oncology. 34. S1149–S1150.
3.
4.
Tarantino, Paolo, Qingchun Jin, Rinath Jeselsohn, et al.. (2022). 1MO Prognostic and biologic significance of HER2-low expression in early breast cancer. Annals of Oncology. 33. S124–S124. 5 indexed citations
5.
Antonarelli, Gabriele, Chiara Corti, Paolo Tarantino, et al.. (2021). Therapeutic cancer vaccines revamping: technology advancements and pitfalls. Annals of Oncology. 32(12). 1537–1551. 46 indexed citations
6.
Harbeck, Nadia, Carlos H. Barrios, Shigehira Saji, et al.. (2020). LBA11 IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC). Annals of Oncology. 31. S1144–S1144. 14 indexed citations
7.
Saji, Shigehira, EA Mittendorf, Nadia Harbeck, et al.. (2020). 3MO IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemo in early triple-negative breast cancer (TNBC). Annals of Oncology. 31. S1243–S1243. 2 indexed citations
8.
Hall, Carolyn, Kenneth R. Hess, Gaiane M. Rauch, et al.. (2018). Prognostic implications of circulating tumor cells (CTCs) after neoadjuvant chemotherapy for triple negative breast cancer (TNBC). Annals of Oncology. 29. viii72–viii72. 1 indexed citations
9.
Moulder, Stacy L., Jennifer K. Litton, EA Mittendorf, et al.. (2016). Improving outcomes in triple-negative breast cancer (TNBC) using molecular characterization and diagnostic imaging to identify and treat chemo-insensitive disease. Annals of Oncology. 27. vi67–vi67. 1 indexed citations
10.
Buchholz, Thomas A., et al.. (2015). Surgical Considerations After Neoadjuvant Chemotherapy: Breast Conservation Therapy. JNCI Monographs. 2015(51). 11–14. 33 indexed citations
11.
Mittendorf, EA, Guy T. Clifton, Jarrod P. Holmes, et al.. (2014). Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Annals of Oncology. 25(9). 1735–1742. 189 indexed citations
12.
Li, Xiang, EA Mittendorf, Jiangtao Li, et al.. (2013). Comparison of clinicopathologic features and survival in young American women aged 18–39 years in different ethnic groups with breast cancer. British Journal of Cancer. 109(5). 1302–1309. 22 indexed citations
13.
Papamichail, Michael, et al.. (2013). Abstract P2-14-01: Breast cancer patients with HER2 low-expression: An under-recognized group at significant risk for recurrence. Cancer Research. 73(24_Supplement). P2–14. 1 indexed citations
14.
Papamichail, Michael, et al.. (2013). Abstract P4-13-05: HLA-A2 is not a prognostic indicator in breast cancer: Implications for cancer vaccine trials. Cancer Research. 73(24_Supplement). P4–13. 1 indexed citations
15.
Ponniah, Sathibalan, et al.. (2012). Abstract P5-16-02: Final Results of the Phase I/II Trials of the E75 Adjuvant Breast Cancer Vaccine. Cancer Research. 72(24_Supplement). P5–16. 5 indexed citations
16.
17.
Shumway, Nathan M., et al.. (2011). Sequential administration of trastuzumab and a CD8 T-cell-eliciting HER2/neu peptide vaccine in patients with breast cancer compared to trastuzumab alone.. Journal of Clinical Oncology. 29(15_suppl). 564–564. 2 indexed citations
18.
Mittendorf, EA, et al.. (2011). P1-13-02: Long-Term Clinical Benefit of Adjuvant Breast Cancer Vaccine: 5 Year Efficacy of E75 with Multiple Booster Inoculations.. Cancer Research. 71(24_Supplement). P1–13. 1 indexed citations
19.
Caudle, Abigail S., Ana M. González-Angulo, P. Liu, et al.. (2009). Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. Journal of Clinical Oncology. 27(15_suppl). 603–603. 4 indexed citations
20.
Mittendorf, EA, Catherine E. Storrer, Katie Harris, et al.. (2006). Early results of a phase I clinical trial of an Ii-Key/Her2/neu MHC class II peptide-based vaccine in breast cancer patients. Journal of Clinical Oncology. 24(18_suppl). 2532–2532. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rachel Marty Pyke Breakdown of academic impact, for papers by Winifred Lo Breakdown of academic impact, for papers by Annegé Vledder Breakdown of academic impact, for papers by Jennifer McDevitt Breakdown of academic impact, for papers by Ningning Dong Breakdown of academic impact, for papers by Puay Hoon Tan Breakdown of academic impact, for papers by B. Szynglarewicz Breakdown of academic impact, for papers by Makda Zewde Breakdown of academic impact, for papers by Anna Spille Breakdown of academic impact, for papers by Yun Hua Lee
Rankless by CCL
2026